Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.80 -1.94 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
67 68 Next >
Preview: BioNTech's Earnings
Via Benzinga
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.
The company hopes to launch an updated Covid booster shot this fall. But there are several complications. 
Via Investor's Business Daily
Analyst Ratings for BioNTech
Via Benzinga
BioNTech Completes Acquisition of InstaDeep
From BioNTech SE
Via GlobeNewswire
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair  
Via Benzinga
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement
Deals and financings, trials and approvals in the Chinese biotech/biopharma sphere. 
Via Talk Markets
Expert Ratings for BioNTech
Via Benzinga
Price Over Earnings Overview: BioNTech
Via Benzinga
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
From BioNTech SE
Via GlobeNewswire
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching... 
Via Talk Markets
3 Biotech Stocks That AI is Loving in July
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
Via InvestorPlace
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
Where BioNTech Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
Via Benzinga
Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness
The European Commission has reportedly made arrangements with Pfizer Inc (NYSE: PFE) and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually... 
Via Benzinga
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
From BioNTech SE
Via GlobeNewswire
Big Tech on the Prowl: 3 Potential AI Stock Acquisition Targets
With the artificial intelligence boom gaining momentum, we’re likely to see far more interest in AI stocks. 
Via InvestorPlace
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support
Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v 
Via Benzinga
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger 
Via Benzinga
German Woman Sues BioNTech for €150K Claiming Adverse Effects from COVID-19 Vaccine: What You Need to Know
BioNTech SE (NASDAQ: BNTX) is reportedly scheduled to appear in court on Monday to defend itself against a lawsuit filed by a German woman seeking damages for alleged side effects of BioNTech's... 
Via Benzinga
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
This year’s 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023) provided a surprising amount of clinical data relevant to biopharma investors. 
Via Benzinga
ChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories
Benzinga Cable Giant CNN Chairman, CEO Chris Licht Moves Out 
Via Benzinga
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by 
Via Benzinga
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging... 
Via Benzinga
3 Ugly Stocks That Actually Hide Beautiful Potential
While these underrated stocks with potential has about as much appeal as brown guacamole, they’re actually quite intriguing. 
Via InvestorPlace
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy. 
Via The Motley Fool
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.